NanoCarrier's FVIIa alliance hits bump but cisplatin tie-up forges ahead
This article was originally published in Scrip
Around a year after they extended an initial 2010 option and research collaboration, the French state-owned company LFB Biotechnologies and the Japanese bioventure NanoCarrier have temporarily ended their attempts to develop a novel sustained-release formulation of LFB's human Factor VIIa product for hemophilia.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.